Patent ID: 9163084
Filing Date: 2015-10-20
Classification: A61K,A61P,C07K

Abstract:
1. A method for monitoring the efficacy of therapy for an inflammatory disease, comprising measuring CXCR3 protein in a first sample from a subject having an inflammatory disease, wherein the CXCR3 expression is increased from normal expression, initiating therapy, and measuring CXCR3 protein in a second sample from the subject, wherein a decrease in the quantity of CXCR3 protein in the second sample can be indicative of efficacy of the therapy, wherein the measuring of CXCR3 protein comprises contacting the samples with an antibody or antigen-binding fragment thereof which binds a CXCR3 protein, and a) said antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) comprising the amino acid sequences: three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) comprising the amino acid sequences: b) said antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) comprising the amino acid sequences: three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) comprising an amino acid sequences: